menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Incretin Treatment Options: What's New & in the Pipeline?

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Host Dr. Farhad Zenganah is joined by Dr. Robert Busch and they will be discussing current incretin treatment options and what is in the pipeline. They will discuss the differences between oral and injectables incretin treatment options and how clinicians can individualize treatment options for their patients, while determining the benefits and risks. 

    Robert Busch, MD, is a practicing endocrinologist and founding member of The Endocrine Group in Albany, New York. Dr. Busch is a member of the board of trustees at the Albany College of Pharmacy. He has enthusiastically enjoyed teaching medical students, pharmacists, physician assistants, nurse practitioners, and physicians for over 25 years.He is a principal investigator in numerous clinical trials.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Host Dr. Farhad Zenganah is joined by Dr. Robert Busch and they will be discussing current incretin treatment options and what is in the pipeline. They will discuss the differences between oral and injectables incretin treatment options and how clinicians can individualize treatment options for their patients, while determining the benefits and risks. 

    Robert Busch, MD, is a practicing endocrinologist and founding member of The Endocrine Group in Albany, New York. Dr. Busch is a member of the board of trustees at the Albany College of Pharmacy. He has enthusiastically enjoyed teaching medical students, pharmacists, physician assistants, nurse practitioners, and physicians for over 25 years.He is a principal investigator in numerous clinical trials.

Facebook Comments

Schedule25 Apr 2024